An ongoing dispute between a Canadian cannabis company and a group of dissatisfied investors reached its conclusion this past week.
Meanwhile, a company managing a cannabis cultivator based in Colombia told investors that its UK expansion plan is now underway.
Keep reading to find out more cannabis highlights from the past five days.
Investor group takes over Australis management team in surprising win
It’s a time of change for Australis Capital (AUSA) (CSE:AUSA,OTCQB:AUSAF), which confirmed the victory of the Concerned Shareholders of Australis Capital at its annual and special meeting of shareholders. The Concerned Shareholders had been leading a takeover dispute against AUSA’s management.
Before the official vote took place, the board nominees put forward by AUSA were withdrawn, leaving the nominees from the Concerned Shareholders to win seats on the AUSA board of directors.
Duke Fu, one of the newly elected AUSA board members, said there is significant work ahead to edge the company towards becoming a US cannabis operation. “We thank all shareholders for their involvement, support and patience during this process. Our mission to move the Company forward is front and centre,” he said in a statement.
Terry Booth, a leading member of the Concerned Shareholders, has been retained as a consultant for the company moving forward. In a statement, Booth said he is excited for the future of the company and pointed to the will of investors as the motivation for the new management team.
“There is simply no alternative, shareholders expect and deserve accretive growth without delay. It is indeed time to ignite, excite and delight this loyal shareholder base,” said Booth, who is the founder and former CEO of Aurora Cannabis (NYSE:ACB,TSX:ACB).
With this change confirmed, the former AUSA management team issued their resignations from the company — CEO Harry DeMott, CFO Alex Han, COO Cleve Tzung and Daniel Norr, executive vice president and chief legal officer, all stepped down.
The election results helped shares of the company jump in value this past week. As of Friday (November 20) at 11:37 a.m. EST, shares of AUSA were worth C$0.20 each. Over the past five trading days, the company went up nearly 30 percent.
Colombian cannabis producer sets eyes for UK market
The Toronto-based company, which is managing a cannabis producer in Colombia, confirmed it has a deal in place with its distribution partner that will last until Q1 2021. This arrangement will allow PharmaCielo to ship up to 1,000 kilograms of product during the Q1 2021 period.
Moving forward, PharmaCielo expects to obtain a novel foods authorization for its CBD extracts, at which point it will be able to expand its product offerings throughout its fiscal 2021 year. The permit would indicate that the company meets regulatory market standards.
David Attard, CEO of PharmaCielo, said he expects 2021 to be a critical year for the company as it continues to attempt its expansion plans across the international cannabis markets.
Cannabis company news
- TerrAscend (CSE:TER,OTCQX:TRSSF) gave investors an official look at its Q3 performance period, during which sales came to C$51 million and adjusted EBITDA increased to C$17.8 million. Jason Ackerman, CEO and executive chairman of TerrAscend, highlighted the Pennsylvania and New Jersey markets for the company.
- Charlotte’s Web Holdings (TSX:CWEB,OTCQX:CWBHF) will look into the therapeutic use of cannabinoids via a new research project done in collaboration with the University at Buffalo’s Center for Integrated Global Biomedical Sciences.
- Neptune Wellness Solutions (NASDAQ:NEPT,TSX:NEPT) issued financial results for its second fiscal quarter of 2021, reporting a net loss of C$21,840 despite a total revenue spike to C$28,686.
- Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) reported its Q3 results, highlighting a 13 percent revenue increase to US$136.3 million. Overall, the company reported net income of US$17.4 million and adjusted EBITDA of US$67.5 million.
- Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) took the opportunity in its Q3 financial report to announce the succession plan for CEO Joseph Lusardi, who will be transitioning away from the role. Curaleaf President Joseph Bayern has been appointed as the next leader.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.